Marion Merrell Dow
This article was originally published in The Tan Sheet
Executive Summary
Licenses terfenadine carboxylate use patent from separations technology company Sepracor for $ 7.5 mil. In addition, MMD is acquiring a 5.9% equity stake in Marlborough, Mass.-based Sepracor for $ 10 mil. MMD has been developing a terfenadine carboxylate and holds a composition patent that is valid through 1998. The Seldane metabolite has been shown to be non-cardiotoxic. Reports of Seldane cardiovascular adverse events have badly damaged the product's potential for OTC marketing.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning